Jun C.

- In Crossroads Institute, as Abbott Professional Education Manager, was responsible for primary, intermediate and advanced training of cardiovascular interventional physicians. According to the strategy of the Central Marketing Department and the focus of promotion, design and develop year-round professional training plans and courses for different customers. Delivered key message of Abbott products and guided to target customers, to familiarize themselves with Abbott products to meet customer needs and apply them to clinical practice. - Updating of the database of KOLs and experts in the year, good relations with experts, utilized national experts to drive and mentor local experts and delivered key messages - Crossroads national core course were executed 4/ year, regional course were 20/ year, simulator operation were 2-4 sessions. - 2020 special epidemic situation ,4 new online professional education courses, using live operation, video recording, review case discussion, lecture teaching, case sharing, national multi-center operation live exchange, hot discussion of academic topics, the teaching of new technology and new equipment has been praised by doctors on the spot and online. - Simulator teaching is a good method for junior students to practice hands Promoted the consensus of Chinese experts in OCT imaging - To obtain professional certification of imaging OCT and functional FFR, to support and guidance for accurate treatment of PCI

Coronary products management: Manage BMS, BDC, GW Core CT products: Vision, VOYAGER, TREK, BMWUII, ADVANCE etc.. Directly report to marketing manager/MD. I was charge of Xience DES and manage the products from 2014. And be charge of some projects to well execute DES stent strategy and plan from May, 2017. - Make CT products marketing strategy and plan, short-term and long term - Successfully launched many new products in China during seven years in Abbott Vascular. Launched Stent Xience V, Balloon VOYAGER NC in China in 2009, launched Guidewire BMWUII and ADVACE in China in 2010Q4, launched Balloon TREK in China in 2011, launched Balloon MINI TREK in China in 2012 and launched NC TREK in 2013 & BMW Elite in 2014. - Collected market information and competitor’s information, analysis and compare, supply for decision - Organized and executed marketing activities, monitor, tracking and follow-up. Communicate with other function and department. And finally reach the sales target and increase market share - Built well relationships with KOLs and Key physicians, deliver key message and new technology and find out their clinical needs - Training include product knowledge and medical key message The market share was maintained and increased. For DES NO1 13%MS in big 4 MNC, BDC NO2 33%MS and GW NO1 55%MS. The revenue of DES stent was achieved 800 MM RMB in 2016. Main target department is vascular intervention department.

District Manager: manage one team of CV,another team of SP - The total sales share is 50% in region and value is 24.5 mio RMB. Achieved 100% target in 2005 and increased 18% vs 2004. - Promoted in Cardiovascular medicine, Nephrology, Hematology, Anesthesiology and other department. Communicated well with customers. - Develop 27 tier II, tier III hospitals. - Manage Jiangxi Province sales team in 2002 and 2003 Product Manager:Manage two products of anemia: Niferex and CosmoFer, one is oral and another is iv iron. Directly report to marketing director - Make the Niferex & CosmoFer products marketing strategy and plan, short-term and long term - Collected market information and competitor’s information, analysis and compare, supply for decision - Communicate with other departments, organize marketing activities, monitor and follow-up. Reach the sales target and increase market share - Training include product knowledge and medical key message the performance increase every year, especially Niferex 40% increase every year and the performance is from 58 mio RMB to 102 mio RMB during 2006 to 2008 The market share increase from 11% to 15% during 2006 to 2008 Main target department is Nephrology, O&G, Hematology, GI, Oncology and other associated department. Especially relationship with KOLs in Nephrology and O& G